{"entity":{"id":"nct04374630","kind":"trial","name":"Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian","aka":[],"tldr":"A phase 2 trial of Afuresertib run by Laekna Limited, completed.","summary":"Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian is a phase 2 interventional study registered as NCT04374630 by Laekna Limited, with 150 participants enrolled, started 2020-07-07, primary completion reached 2023-10-31. Conditions recorded: Platinum-resistant Ovarian Cancer. Interventions recorded: Paclitaxel, Afuresertib.","status":"completed","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT04374630","url":"https://clinicaltrials.gov/study/NCT04374630"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["afuresertib"],"companies":["laekna-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04374630","phase":"2","setting":"An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer","sponsor":"Laekna Limited","enrolled":150,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04374630/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"afuresertib","kind":"drug","name":"Afuresertib","route":"/drugs/afuresertib/"}],"company":[{"id":"laekna-therapeutics","kind":"company","name":"Laekna Therapeutics","route":"/companies/laekna-therapeutics/"}]}}